SCHEMBL33527124

SCHEMBL33527124

N#Cc1c(N)sc2c(F)ccc(-c3c4c(c5c(NC6CC[C@H]7CCN7C6=O)ncnc5c3Cl)COC4)c12

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KRAS P01116 5/20 0.43
BTK Q06187 5/20 0.34
PIK3CD O00329 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33526235 0.96 KRAS (0.42) KRASBTK
SCHEMBL33526104 0.86 BTK (0.35) KRASBTKPIK3CD
SCHEMBL33525656 0.85 KRAS (0.38) KRASBTK
SCHEMBL33525757 0.85 GPR119 (0.33) KRASBTK
SCHEMBL33526211 0.85 BTK (0.37) KRASBTKPIK3CD
SCHEMBL33526105 0.84 KRAS (0.41) KRAS
SCHEMBL33526669 0.84 PIK3CD (0.35) BTKPIK3CD
SCHEMBL33525601 0.84 KRAS (0.36) KRASBTKPIK3CD
SCHEMBL33525729 0.83 KRAS (0.36) KRASBTK
SCHEMBL33525603 0.83 KRAS (0.36) KRASBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600733-B2 KRAS inhibitors ELI LILLY AND COMPANY (US) 2026-04-14 US disclosed
US-20260092075-A1 KRAS INHIBITORS LILLY CO ELI (US) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600733-B2 KRAS inhibitors KRAS, NRAS, HRAS KRAS 1/4885BTK 350/4885PIK3CD 266/4885
US-20260092075-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KRAS 1/4885BTK 389/4885PIK3CD 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.